Evidence map›Paper›PMID 41088409›Full record

ReviewMolecular neurodegeneration2025

Modeling neurodegeneration in the retina and strategies for developing pan-neurodegenerative therapies.

Emily L Ward, Larry Benowitz, Thomas M Brunner, Guojun Bu, Michel Cayouette, Valeria Canto-Soler, Sandro Dá Mesquita, Adriana Di Polo, Aaron DiAntonio, Xin Duan and 13 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Emily L WardHerbert Wertheim School of Optometry & Vision Science, University of California Berkeley, Berkeley, CA, USA.
Larry BenowitzDepartment of Neurosurgery and F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Thomas M BrunnerGlaucoma Research Foundation, San Francisco, CA, USA.
Guojun BuDivision of Life Science, Hong Kong University of Science and Technology, Hong Kong, China.
Michel CayouetteMolecular Biology Program, Université de Montréal, Montreal, Canada.
Valeria Canto-SolerCellSight Ocular Stem Cell and Regeneration Research Program, Department of Ophthalmology, University of Colorado School of Medicine, Sue Anschutz-Rodgers Eye Center, Aurora, CO, USA.
Sandro Dá MesquitaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Adriana Di PoloDepartment of Neuroscience, University of Montreal, Montreal, QC, Canada.
Aaron DiAntonioNeedleman Center for Neurometabolism and Axonal Therapeutics, St. Louis, MO, USA.
Xin DuanDepartment of Ophthalmology, University of California San Francisco, San Francisco, CA, USA.
Jeffrey L GoldbergSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Zhigang HeF.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, USA.
Yang HuSpencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
Shane A LiddelowNeuroscience Institute, NYU Grossman School of Medicine, New York, NY, USA.
Anna La TorreDepartment of Cell Biology and Human Anatomy, University of California Davis, Davis, CA, USA.
Milica MargetaDepartment of Ophthalmology, Harvard Medical School, Mass Eye and Ear, Boston, MA, USA.
Francisco QuintanaDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Karthik ShekharDepartment of Chemical and Biomolecular Engineering, Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.
Beth StevensDepartment of Neurology, F.M. Kirby Neurobiology Center, Howard Hughes Medical Institute, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Sally TempleNeural Stem Cell Institute, Albany, NY, USA.
Humsa VenkateshDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Derek WelsbieShiley Eye Institute and Viterbi Family Department of Ophthalmology, University of California, San Diego, CA, USA.
John G FlanaganHerbert Wertheim School of Optometry & Vision Science, University of California Berkeley, Berkeley, CA, USA. jgflanagan@berkeley.edu.

Funding

TRAINING PROGRAM IN VISION SCIENCET32EY007043 · NEI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Suzanne MJ FLEISZIG · 1985 to 2026
$12.9M
Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
BRAIN CONNECTS: Scalable Approaches for Bidirectional Brain-wide Trans-Neuronal Connectivity Mapping of Defined Cell TypesU01NS136405 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Xin Duan, Evan Harriman Feinberg · 2024 to 2026
$5.9M
Elucidating Neuron-Intrinsic Molecular Mechanisms of Optic Nerve RegenerationR01EY024932 · NEI · TEMPLE UNIV OF THE COMMONWEALTH · PI Yang Hu · 2015 to 2026
$4.8M
Mechanisms Underlying Type II Cadherin Guided Assembly of Retinal CircuitsR01EY030138 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Xin Duan · 2020 to 2026
$3.2M
In Vivo Function and Metabolism Evaluation of Glaucomatous RGCs by Two-Photon Scanning Laser OphthalmologyR01EY034353 · NEI · STANFORD UNIVERSITY · PI Yang Hu, Hao F Zhang · 2023 to 2026
$2.7M
Optineurin dysfunction induces neurodegeneration in normal tension glaucoma by a novel molecular mechanismR01EY032518 · NEI · STANFORD UNIVERSITY · PI Yang Hu · 2022 to 2026
$2.7M
Developing ER Stress Chemical Modulators as Neuroprotectants for GlaucomaR01EY036943 · NEI · STANFORD UNIVERSITY · PI Yang Hu · 2025 to 2026
$1.0M
NEI NIH HHS P30 EY026877NEI NIH HHS R01 EY024932NEI NIH HHS R01 EY030138NEI NIH HHS R01 EY032518NEI NIH HHS R01 EY034353NEI NIH HHS R01 EY036943NEI NIH HHS T32 EY007043NINDS NIH HHS U01 NS136405
6 · The paper itself

Abstract

backgroundGlaucoma Research Foundation's third Catalyst for a Cure team (CFC3) was established in 2019 to uncover new therapies for glaucoma, a leading cause of blindness. In the 2021 meeting "Solving Neurodegeneration," (detailed in Mol Neurodegeneration 17(1), 2022) the team examined the failures of investigational monotherapies, issues with translatability, and other significant challenges faced when working with neurodegenerative disease models. They emphasized the need for novel, humanized models and proposed identifying commonalities across neurodegenerative diseases to support the creation of pan-neurodegenerative disease therapies. Since then, the fourth Catalyst for a Cure team (CFC4) was formed to explore commonalities between glaucoma and other neurodegenerative diseases. This review summarizes outcomes from the 2023 "Solving Neurodegeneration 2" meeting, a forum for CFC3 and CFC4 to share updates, problem solve, plan future research collaborations, and identify areas of unmet need or opportunity in glaucoma and the broader field of neurodegenerative disease research. MAIN BODY: We summarize the recent progress in the field of neurodegenerative disease research and present the newest challenges and opportunities moving forward. While translatability and disease complexity continue to pose major challenges, important progress has been made in identifying neuroprotective targets and understanding neuron-glia-vascular cell interactions. New challenges involve improving our understanding of the disease microenvironment and timeline, identifying the optimal approach(es) to neuronal replacement, and finding the best drug combinations and synergies for neuroprotection. We propose solutions to common research questions, provide prescriptive recommendations for future studies, and detail methodologies, strategies, and approaches for addressing major challenges at the forefront of neurodegenerative disease research.

conclusionsThis review is intended to serve as a research framework, offering recommendations and approaches to validating neuroprotective targets, investigating rare cell types, performing cell-specific functional characterizations, leveraging novel adaptations of scRNAseq, and performing single-cell sorting and sequencing across neurodegenerative diseases and disease models. We focus on modeling neurodegeneration using glaucoma and other neurodegenerative pathologies to investigate the temporal and spatial dynamics of neurodegenerative disease pathogenesis, suggesting researchers aim to identify pan-neurodegenerative drug targets and drug combinations leverageable across neurodegenerative diseases.

Indexed as

GlaucomaNeurodegenerative DiseasesNeuroprotectionRetinaAnimalsCellular ReprogrammingDisease Models, AnimalHumansRetinal Ganglion CellsAlzheimer’s DiseaseAmyotrophic lateral sclerosisGlaucomaGliaNeurodegenerationNeuroinflammationNeuroprotectionParkinson’s DiseaseRetinal ganglion cellsRetinal pathologies

Identifiers

PMID41088409
PMCPMC12523214

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.